Cancer immunotherapy trials: leading a paradigm shift in drug development.
作者信息
Emens Leisha A, Butterfield Lisa H, Hodi F Stephen, Marincola Francesco M, Kaufman Howard L
机构信息
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans Street, Room 409, Baltimore, MD 21231-1000 USA.
Departments of Medicine, Surgery, and Immunology, Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA USA.
出版信息
J Immunother Cancer. 2016 Jul 19;4:42. doi: 10.1186/s40425-016-0146-9. eCollection 2016.
Abstract
摘要
相似文献
1
Cancer immunotherapy trials: leading a paradigm shift in drug development.
J Immunother Cancer. 2016 Jul 19;4:42. doi: 10.1186/s40425-016-0146-9. eCollection 2016.
2
Perspectives on the design of clinical trials for targeted therapies and immunotherapy in veterinary oncology.
Vet J. 2015 Aug;205(2):238-43. doi: 10.1016/j.tvjl.2015.02.020. Epub 2015 Mar 3.
3
Algenpantucel-L immunotherapy in pancreatic adenocarcinoma.
Immunotherapy. 2016 Feb;8(2):117-25. doi: 10.2217/imt.15.113. Epub 2016 Jan 20.
4
Active specific immunotherapy and cell-transfer therapy for the treatment of non-small cell lung cancer.
Lung Cancer. 2009 Jul;65(1):1-8. doi: 10.1016/j.lungcan.2008.10.018. Epub 2008 Dec 4.
5
Employing dynamical computational models for personalizing cancer immunotherapy.
Expert Opin Biol Ther. 2016 Nov;16(11):1373-1385. doi: 10.1080/14712598.2016.1223622. Epub 2016 Aug 26.
6
Improved melanoma survival at last! Ipilimumab and a paradigm shift for immunotherapy.
Pigment Cell Melanoma Res. 2010 Oct;23(5):580-1. doi: 10.1111/j.1755-148X.2010.00737.x. Epub 2010 Jul 16.
7
Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer.
Clin Cancer Res. 2015 Mar 1;21(5):976-84. doi: 10.1158/1078-0432.CCR-14-1187.
8
A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.
Immunol Rev. 2008 Apr;222:316-27. doi: 10.1111/j.1600-065X.2008.00605.x.
9
Biomarker-driven early clinical trials in oncology: a paradigm shift in drug development.
Cancer J. 2009 Sep-Oct;15(5):406-20. doi: 10.1097/PPO.0b013e3181bd0445.
10
Immunotherapy and radiation therapy: considerations for successfully combining radiation into the paradigm of immuno-oncology drug development.
Radiat Res. 2014 Aug;182(2):252-7. doi: 10.1667/RR13707.1. Epub 2014 Jul 8.
引用本文的文献
1
Computationally integrating radiology and pathology image features for predicting treatment benefit and outcome in lung cancer.
NPJ Precis Oncol. 2025 Jun 4;9(1):161. doi: 10.1038/s41698-025-00939-0.
2
Targeting Cbl-b in cancer immunotherapy.
J Immunother Cancer. 2023 Feb;11(2). doi: 10.1136/jitc-2022-006007.
3
Integration of healthy volunteers in early phase clinical trials with immuno-oncological compounds.
Front Oncol. 2022 Aug 29;12:954806. doi: 10.3389/fonc.2022.954806. eCollection 2022.
4
Identification of novel pyrrolopyrimidine and pyrrolopyridine derivatives as potent ENPP1 inhibitors.
J Enzyme Inhib Med Chem. 2022 Dec;37(1):2434-2451. doi: 10.1080/14756366.2022.2119566.
5
Advancing microfluidic diagnostic chips into clinical use: a review of current challenges and opportunities.
Lab Chip. 2022 Aug 23;22(17):3110-3121. doi: 10.1039/d2lc00024e.
6
Albumin and interferon-β fusion protein serves as an effective vaccine adjuvant to enhance antigen-specific CD8+ T cell-mediated antitumor immunity.
J Immunother Cancer. 2022 Apr;10(4). doi: 10.1136/jitc-2021-004342.
7
The MAPK hypothesis: immune-regulatory effects of MAPK-pathway genetic dysregulations and implications for breast cancer immunotherapy.
Emerg Top Life Sci. 2017 Dec 12;1(5):429-445. doi: 10.1042/ETLS20170142.
8
Identification and Management of Posterior Reversible Encephalopathy Syndrome in a Patient Enrolled in an Immunotherapy Combination Phase I Clinical Trial: A Case Study.
Asia Pac J Oncol Nurs. 2020 Nov 21;8(1):103-105. doi: 10.4103/apjon.apjon_49_20. eCollection 2021 Jan-Feb.
9
Fractional design: An alternative paradigm for late-onset toxicities in oncology dose-finding studies.
Contemp Clin Trials Commun. 2020 Aug 18;19:100650. doi: 10.1016/j.conctc.2020.100650. eCollection 2020 Sep.
10
Novel strategies in immune checkpoint inhibitor drug development: How far are we from the paradigm shift?
Br J Clin Pharmacol. 2020 Sep;86(9):1753-1768. doi: 10.1111/bcp.14355. Epub 2020 Jun 13.
本文引用的文献
1
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.
J Clin Oncol. 2016 May 1;34(13):1510-7. doi: 10.1200/JCO.2015.64.0391. Epub 2016 Mar 7.
2
Novel technologies and emerging biomarkers for personalized cancer immunotherapy.
J Immunother Cancer. 2016 Jan 19;4:3. doi: 10.1186/s40425-016-0107-3. eCollection 2016.
3
Expansion Cohorts in First-in-Human Solid Tumor Oncology Trials.
Clin Cancer Res. 2015 Oct 15;21(20):4545-51. doi: 10.1158/1078-0432.CCR-14-3244.
4
Advancing Clinical Trials to Streamline Drug Development.
Clin Cancer Res. 2015 Oct 15;21(20):4527-35. doi: 10.1158/1078-0432.CCR-15-0039.
5
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
N Engl J Med. 2015 Oct 22;373(17):1627-39. doi: 10.1056/NEJMoa1507643. Epub 2015 Sep 27.
6
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.
N Engl J Med. 2015 Nov 5;373(19):1803-13. doi: 10.1056/NEJMoa1510665. Epub 2015 Sep 25.
7
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia.
Sci Transl Med. 2015 Sep 2;7(303):303ra139. doi: 10.1126/scitranslmed.aac5415.
8
Oncolytic viruses: a new class of immunotherapy drugs.
Nat Rev Drug Discov. 2015 Sep;14(9):642-62. doi: 10.1038/nrd4663.
9
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
N Engl J Med. 2015 Jul 9;373(2):123-35. doi: 10.1056/NEJMoa1504627. Epub 2015 May 31.
10
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
N Engl J Med. 2015 Jul 2;373(1):23-34. doi: 10.1056/NEJMoa1504030. Epub 2015 May 31.
Zotero 插件